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As Covid-19 continues to exact a heavy toll, development of a vaccine appears the most promising means of restoring normalcy to 
civil life. Perhaps no scientific breakthrough is 
more eagerly anticipated. But 
bringing a vaccine to market is 
only half the challenge; also crit-
ical is ensuring a high enough 
vaccination rate to achieve herd 
immunity. Concerningly, a recent 
poll found that only 49% of 
Americans planned to get vacci-
nated against SARS-CoV-2.1
One option for increasing vac-
cine uptake is to require it. Man-
datory vaccination has proven ef-
fective in ensuring high childhood 
immunization rates in many 
high-income countries. However, 
except for influenza vaccination 
of health care workers, mandates 
have not been widely used for 
adults.
Although a vaccine remains 
months to years away, developing 
a policy strategy to ensure uptake 
takes time. We offer a framework 
that states can apply now to help 
ensure uptake of the vaccine 
when it becomes available — in-
cluding consideration of when a 
mandate might become appro-
priate. Our approach is guided by 
lessons from U.S. experiences 
with vaccines for the 1976 “swine 
flu,” H1N1 influenza, smallpox, 
and human papillomavirus (HPV).
We believe that six substantive 
criteria should be met before a 
state imposes a SARS-CoV-2 vac-
cine mandate (see box). The first 
is the existence of evidence that 
Covid-19 is inadequately con-
trolled in the state by other mea-
sures, such as testing, contact 
tracing, and isolation and quar-
antine — as indicated by sus-
tained, troubling trends in new 
cases, hospitalizations, or deaths. 
Principles of public health law 
and ethics require that interven-
tions that impinge on autonomy 
be reasonable and necessary; 
therefore, Covid-19 must present 
an ongoing threat. By the time a 
vaccine is available, more will be 
known about natural immunity 
in the population, the conse-
quences of relaxing community 
mitigation measures, and the fea-
sibility of scaling up test-and-trace 
strategies. There should be a rea-
sonable indication as to whether 
further measures are needed.
The second criterion is that 
the Advisory Committee on Im-
munization Practices (ACIP), af-
ter reviewing the safety and effi-
cacy evidence, has recommended 
vaccination for the persons who 
would be covered by a mandate. 
Currently available evidence sug-
gests that the elderly, health pro-
fessionals working in high-risk 
situations or working with high-
risk patients (e.g., nursing home 
residents and patients with se-
vere respiratory symptoms), and 
persons with certain underlying 
medical conditions may be high-
priority groups for the ACIP’s 
consideration, along with other 
Ensuring Uptake of Vaccines against SARS-CoV-2
Michelle M. Mello, J.D., Ph.D., Ross D. Silverman, J.D., M.P.H., and Saad B. Omer, M.B., B.S., M.P.H., Ph.D. 
Ensuring Uptake of Vaccines against SARS-CoV-2
PERSPECTIVE
2
Ensuring Uptake of Vaccines against SARS-CoV-2
n engl j med nejm.org  
workers with frequent, close, on-
the-job contacts and persons liv-
ing in high-density settings such 
as prisons and dormitories. When 
a vaccine nears approval, the ACIP 
should review the updated evi-
dence and develop recommenda-
tions. Only recommended groups 
should be considered for a vacci-
nation mandate, though health 
officials can encourage voluntary 
uptake for others, using means 
such as public education cam-
paigns and free vaccination.
The fact that a vaccine has re-
ceived Food and Drug Adminis-
tration (FDA) approval — wheth-
er under an Emergency Use 
Authorization (EUA) or ordinary 
review processes — is an insuf-
ficient basis on which to con-
clude that it should be required. 
FDA approval reflects a determi-
nation that clinical trial evidence 
shows that the benefits of a vac-
cine outweigh its risks. ACIP rec-
ommendations reflect broader 
considerations, including values 
and preferences of affected groups, 
implementation issues, and health 
economic analyses. Overweight-
ing FDA decisions would be par-
ticularly problematic for SARS-
CoV-2 vaccines because EUAs may 
be based on very limited evidence 
and consciously or unconsciously 
influenced by the intense pres-
sure to speed countermeasures 
to market.2
The third criterion is that 
there is an adequate supply of 
vaccine to cover the groups for 
which a mandate is being con-
sidered. Initially, global demand 
for SARS-CoV-2 vaccines will out-
strip supply, making the salient 
question not who must get them 
but who will be granted access 
to them. New York State’s unsuc-
cessful attempt to mandate H1N1 
influenza vaccination for health 
care workers demonstrates that 
imposing requirements before ad-
equate supply has been secured 
needlessly provokes controversy 
and alienates people who have 
already made sacrifices to fight 
an epidemic.3
The fourth criterion is that 
there has been transparent com-
munication of the best available 
evidence about the vaccine’s safe-
ty and efficacy.4 Particularly giv-
en the possibility that the evi-
dence underlying FDA approval 
of SARS-CoV-2 vaccines may be 
more modest than usual, policy-
makers and the public will need 
to understand the limits of what 
is known. Public trust has al-
ready been compromised by fed-
eral officials’ endorsement of hy-
droxychloroquine as a Covid-19 
treatment without evidentiary 
support; the same must not oc-
cur for vaccines.
The fifth criterion is that the 
government has put in place cer-
tain support mechanisms for per-
sons required to receive the vac-
cine. Lessons from past vaccination 
campaigns suggest that a gener-
ous compensation program for 
people who have serious vaccine 
side effects should be a centerpiece 
of these efforts. A federal compen-
sation fund like the Smallpox Vac-
cine Injury Compensation Pro-
gram is one attractive model, 
although identifying compensa-
ble injuries may be challenging 
with a novel vaccine. States will 
also have to create distribution 
systems to provide SARS-CoV-2 
vaccine to high-priority groups 
with near-zero financial and lo-
gistic barriers — for example, 
bringing free vaccine to points of 
care, pharmacies, and work sites. 
It is equally critical to have a 
safety-assessment plan in place 
before vaccines are widely dis-
tributed to enable health officials 
to evaluate safety evidence in real 
time. States should work with 
health systems to ensure that re-
porting systems for vaccine-relat-
ed adverse events are consistently 
used and specify a process for 
reconsidering mandate decisions 
as evidence evolves.
The last criterion is that vac-
cination mandates are imposed 
only after a time-limited trial of 
voluntary vaccine provision has 
proved unsuccessful. Principles 
of public health ethics support 
trying less burdensome policies 
before moving to more burden-
some ones whenever possible. In 
this case, the costs of a failed 
voluntary scheme are sufficiently 
high that the attempt should be 
limited to a matter of weeks. 
States should implement a system 
for measuring vaccine uptake 
within each high-priority group 
against a set of coverage targets. 
Ensuring that the economic and 
logistic supports described above 
are in place will maximize the 
chances for success.
Six Trigger Criteria for State Covid-19 Vaccination 
Mandates.
Covid-19 is not adequately contained in the state.
The Advisory Committee on Immunization 
Practices has recommended vaccination for 
the groups for which a mandate is being con-
sidered.
The supply of vaccine is sufficient to cover the 
population groups for which a mandate is be-
ing considered.
Available evidence about the safety and efficacy of 
the vaccine has been transparently communi-
cated.
The state has created infrastructure to provide ac-
cess to vaccination without financial or logis-
tic barriers, compensation to workers who 
have adverse effects from a required vaccine, 
and real-time surveillance of vaccine side ef-
fects.
In a time-limited evaluation, voluntary uptake of 
the vaccine among high-priority groups has 
fallen short of the level required to prevent ep-
idemic spread.
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If the proposed trigger criteria 
were met, what might a vaccina-
tion mandate look like? Because 
the constitutional power to pro-
tect public health rests primarily 
with states, each state will need 
to adopt its own legislation. Pro-
posed legislation should be sup-
ported by attestations from the 
state health officer, the ACIP, or 
another expert committee that 
all trigger criteria have been met. 
Targeted SARS-CoV-2 vaccination 
mandate policies may also be ap-
propriate in certain federal con-
texts, including high-risk groups 
in active-duty military environ-
ments, Veterans Affairs facilities, 
federal prisons, and immigration 
detention centers.
Although state vaccination 
mandates are usually tied to school 
and day care entry, that approach 
is not appropriate for SARS-CoV-2 
because children won’t be a high-
priority group. In addition, state 
mandates should not be structured 
as compulsory vaccination (abso-
lute requirements); instead, non-
compliance should incur a penalty. 
Nevertheless, because of the in-
fectiousness and dangerousness 
of the virus, relatively substantive 
penalties could be justified, in-
cluding employment suspension 
or stay-at-home orders for persons 
in designated high-priority groups 
who refuse vaccination. Neither 
fines nor criminal penalties should 
be used, however; fines disadvan-
tage the poor, and criminal pen-
alties invite legal challenges on 
procedural due-process grounds. 
Both are bad public health policy 
for a Covid-19 vaccine because 
they may stoke distrust without 
improving uptake.
The need to build public trust 
requires that state officials imple-
ment vaccination policy through a 
transparent and inclusive process, 
working closely with stakeholder 
groups such as local health offi-
cers, health professional and hos-
pital associations, representatives 
of high-risk population groups, 
and groups concerned about vac-
cine safety. States’ experience with 
HPV vaccination mandates offers 
another process tip: vaccine man-
ufacturers should stay on the 
sidelines. The HPV vaccine man-
ufacturer’s direct involvement in 
crafting and lobbying for man-
date legislation raised suspicion 
that profit rather than public 
health motives lay behind such 
proposals, undercutting support 
for vaccination even without a 
mandatory regime.5
As with social distancing or-
ders, we can expect that the ad-
vent of SARS-CoV-2 vaccines will 
spark intense clashes of feeling 
about what people owe to one 
another in the fight against the 
pandemic. In contrast to earlier 
phases of the pandemic, though, 
we currently have some time on 
our side. Careful deliberation now 
about state vaccination policy can 
help ensure that we have a strate-
gy when the breakthrough comes.
Disclosure forms provided by the au-
thors are available at NEJM.org.
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